The potential role of Keap1-Nrf2 pathway in the pathogenesis of Alzheimer’s disease, type 2 diabetes, and type 2 diabetes-related Alzheimer’s disease

被引:0
|
作者
Ling He
Yi Sun
机构
[1] China Pharmaceutical University,Department of Pharmacology, School of Pharmacy
来源
Metabolic Brain Disease | 2021年 / 36卷
关键词
Alzheimer’s disease; Diabetes mellitus; Oxidative stress; Keap1-Nrf2 signaling pathway; Antioxidant agents;
D O I
暂无
中图分类号
学科分类号
摘要
Kelch-like ECH associated-protein 1 (Keap1)-nuclear factor erythroid 2-related factor 2 (Nrf2) signaling pathway is thought to be the key regulatory process defensing oxidative stress in multiple organs. Type 2 diabetes mellitus (T2DM) and Alzheimer’s disease (AD) are both serious global health problems with high prevalence. A growing number of literatures have suggested a possible link between Keap1-Nrf2 signaling pathway and the pathological changes of T2DM, AD as well as T2DM-related AD. The current review mainly discusses how the damaged Keap1-Nrf2 signaling pathway leads to dysregulated redox molecular signaling, which may contribute to the pathogenesis of AD and T2DM-related cognitive dysfunction, as well as some compounds targeting this pathway. The further exploration of the mechanisms of this pathway could provide novel therapeutic strategies to improve cognitive function, through restoration of expression or translocation of Nrf2 and scavenging excessive free radicals.
引用
收藏
页码:1469 / 1479
页数:10
相关论文
共 50 条
  • [21] An Association of Virus Infection with Type 2 Diabetes and Alzheimer's Disease
    Karim, Sajjad
    Mirza, Zeenat
    Kamal, Mohammad A.
    Abuzenadah, Adel M.
    Azhar, Esam I.
    Al-Qahtani, Mohammed H.
    Sohrab, Sayed S.
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2014, 13 (03) : 429 - 439
  • [22] Type 2 Diabetes and Late-Onset Alzheimer's Disease
    Cheng, D.
    Noble, J.
    Tang, M. X.
    Schupf, N.
    Mayeux, R.
    Luchsinger, J. A.
    DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2011, 31 (06) : 424 - 430
  • [23] Focus on the Correlations between Alzheimer's Disease and Type 2 Diabetes
    Fiore, Vincenzo
    De Rosa, Antonia
    Falasca, Paolo
    Marci, Massimo
    Guastamacchia, Edoardo
    Licchelli, Brunella
    Giagulli, Vito Angelo
    De Pergola, Giovanni
    Poggi, Antonella
    Triggiani, Vincenzo
    ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS, 2019, 19 (05) : 571 - 579
  • [24] Type 2 Diabetes Mellitus and Alzheimer's Disease: Bridging the Pathophysiology and Management
    Alam, Fahmida
    Islam, Md. Asiful
    Sasongko, Teguh Haryo
    Gan, Siew Hua
    CURRENT PHARMACEUTICAL DESIGN, 2016, 22 (28) : 4430 - 4442
  • [25] Humanin: A Possible Linkage Between Alzheimer's Disease and Type 2 Diabetes
    Mahboobi, Hamidreza
    Golmirzaei, Javad
    Gan, Siew H.
    Jalalian, Mehrdad
    Kamal, Mohammad A.
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2014, 13 (03) : 543 - 552
  • [26] Genomic Linkage Between Alzheimer's Disease and Type 2 Diabetes
    Nedjadi, Taoufik
    Haque, Absarul
    Alam, Qamre
    Gan, Siew H.
    Chaudhary, Adeel G.
    Abuzenadah, Adel M.
    Damanhouri, Ghazi A.
    Kamal, Mohammad A.
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2014, 13 (02) : 203 - 212
  • [27] Alpha-1-Antichymotrypsin: A Common Player for Type 2 Diabetes and Alzheimer's Disease
    Guzman-Herrera, Nataly
    Perez-Najera, Viridiana C.
    Salazar-Olivo, Luis A.
    CURRENT DIABETES REVIEWS, 2021, 17 (05)
  • [28] Direct inhibition of Keap1-Nrf2 Protein-Protein interaction as a potential therapeutic strategy for Alzheimer's disease
    Sun, Yi
    Huang, Jiaxuan
    Chen, Yufei
    Shang, Hao
    Zhang, Wannian
    Yu, Jianqiang
    He, Ling
    Xing, Chengguo
    Zhuang, Chunlin
    BIOORGANIC CHEMISTRY, 2020, 103
  • [29] The Keap1-Nrf2 system and diabetes mellitus
    Uruno, Akira
    Yagishita, Yoko
    Yamamoto, Masayuki
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2015, 566 : 76 - 84
  • [30] Fighting Alzheimer's Disease and Type 2 Diabetes: Pathological links and Treatment Strategies
    Dai, Ying
    Kamal, Mohammad A.
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2014, 13 (02) : 271 - 282